Background
Cellect, LLC held a family of patents covering technology for electronic image sensors. As is common in patent prosecution, different members of the family emerged from the USPTO at different dates with different prosecution histories. Some patents received Patent Term Adjustment (PTA) — an extension of the patent term authorized by Congress under 35 U.S.C. § 154(b) to compensate patentees for administrative delays caused by the USPTO itself, such as examiner backlogs or missed deadlines. These PTA grants caused different family members to have meaningfully different expiration dates.
The USPTO initiated reexamination of Cellect’s patents and raised an obviousness-type double patenting (ODP) rejection. ODP is a judicially created doctrine that prevents a patentee from extending patent rights by obtaining a second patent on an obvious variant of the first — effectively preventing two “bites at the apple” across closely related patents in the same family. Ordinarily, ODP is resolved by filing a terminal disclaimer, which ties the later-expiring patent’s term to the earlier-expiring reference patent. But here, Cellect’s earlier-expiring reference patents had already expired, making a terminal disclaimer impossible to file. Cellect argued that its PTA-extended patents should be judged by their natural expiration date (before PTA), not their extended date. The Board disagreed and found the patents invalid for ODP. Cellect appealed.
The Court’s Holding
The Federal Circuit affirmed in a landmark decision, resolving for the first time how PTA interacts with the ODP doctrine. The court adopted a bright-line rule: when a patent has received PTA, the ODP analysis must use the patent’s expiration date after PTA — not the pre-PTA expiration date. This means a patent that expires later than a reference patent solely because of PTA can still be invalid for ODP, even though the extended term was granted by Congress as compensation for government delay.
The court distinguished PTA from Patent Term Extension (PTE) — the statutory extension available to pharmaceutical patent holders to compensate for FDA regulatory review delays. For PTE, prior precedent held that ODP is assessed using the pre-extension expiration date. PTA is different, the court reasoned, because PTE is a one-time, product-specific grant tied to regulatory approval, while PTA is routinely granted and can create systematic term differentials across an entire patent family. The decision means that patent holders who receive large PTA grants on related patents must carefully consider whether to file terminal disclaimers proactively — or risk ODP invalidity even when the earlier-expiring reference patent has expired.
Key Takeaways
- For ODP purposes, a patent’s expiration date after Patent Term Adjustment is the operative date — not the natural statutory expiration date before PTA.
- A patent with a PTA-extended term can be held invalid for ODP over an earlier-expiring family member, even where filing a terminal disclaimer is no longer possible because the reference patent has expired.
- Patent applicants with related patents in prosecution should proactively file terminal disclaimers to avoid ODP exposure before reference patents expire and the disclaimer option closes.
- PTA and PTE are treated differently for ODP purposes — only PTE-extended expiration dates are excluded from ODP analysis.
Why It Matters
This decision significantly complicates patent portfolio strategy for technology companies that hold large, related patent families — particularly in the semiconductor, electronics, and software industries where patent families routinely include dozens of related patents with varying prosecution histories and PTA grants. Previously, many practitioners assumed that PTA extensions were not subject to ODP challenge, since PTA merely compensates for government-caused delays rather than extending the natural term of the patent.
The ruling requires patent owners to audit their portfolios for ODP exposure created by PTA differentials. Patents that expire significantly later than related family members solely due to PTA may be vulnerable to invalidity challenges even decades into their term. The practical consequence: patent prosecutors should default to filing terminal disclaimers on related applications to tie family members together — even when the PTA difference seems modest — rather than waiting to see if ODP becomes an issue in litigation or reexamination.